Shaobo Ke

Dr. Shaobo Ke


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2023 in International Journal of Surgery
Verified
Journal Article
Open access
XFXiangli Fan
Xiangli Fan
WJWang JIng
Wang JIng
YCYongshun Chen
Yongshun Chen
QHQiu Hu
Qiu Hu
YTYuanyuan Tian
Yuanyuan Tian
YCYongshun Chen
Yongshun Chen
Background: The efficacy of endoscopic therapy on the long-term survival outcomes of T1b oesophageal cancer (EC) is unclear, this study was designed to clarify the survival outcomes of endoscopic therapy and to construct a model for predicting the prognosis in T1b EC patients. Methods: This study was performed using the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2017 of patients with T1bN0M0 EC. Cancer-specific survival (CSS) and overall survival (OS) were compared between endoscopic therapy group, esophagectomy group and chemoradiotherapy group, respectively. Stabilized inverse probability treatment weighting was used as the main analysis method. The propensity score matching method and an independent dataset from our hospital were used as sensitivity analysis. The least absolute shrinkage and selection operator regression (Lasso) was employed to sift variables. A prognostic model was then established and was verified in two external validation cohorts. Results: The unadjusted 5-year CSS was 69.5% (95% CI, 61.5–77.5) for endoscopic therapy, 75.0% (95% CI, 71.5–78.5) for esophagectomy and 42.4% (95% CI, 31.0–53.8) for chemoradiotherapy. After stabilized inverse probability treatment weighting adjustment, CSS and OS were similar in endoscopic therapy and esophagectomy groups (P=0.32, P=0.83), while the CSS and OS of chemoradiotherapy patients were inferior to endoscopic therapy patients (P<0.01, P<0.01). Age, histology, grade, tumour size, and treatment were selected to build the prediction model. The area under the curve of receiver operating characteristics of 1, 3, and 5 years in the validation cohort 1 were 0.631, 0.618, 0.638, and 0.733, 0.683, 0.768 in the validation cohort 2. The calibration plots also demonstrated the consistency of predicted and actual values in the two external validation cohorts. Conclusion: Endoscopic therapy achieved comparable long-term survival outcomes to esophagectomy for T1b EC patients. The prediction model developed performed well in calculating the OS of patients with T1b EC.


21 November 2025 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
BGBo Gu
Bo Gu
SCSi-Yu Chang
Si-Yu Chang
KLKe-Ke Li
Ke-Ke Li
BWBai-Qi Wang
Bai-Qi Wang
SKShaobo Ke
Shaobo Ke
RDRunlei Du
Runlei Du
Hypoxia-inducible factor-1α (HIF-1α) is a key transcriptional regulator in tumor progression, tightly controlled by ubiquitination-mediated proteasomal degradation. While multiple deubiquitinases (DUBs) stabilize HIF-1α, the role of ubiquitin specific peptidase 13 (USP13) in colorectal cancer (CRC) remained undefined. This study aimed to elucidate whether USP13 regulates HIF-1α stability and contributes to CRC pathogenesis. USP13-HIF-1α interaction was assessed via co-immunoprecipitation (co-IP), immunofluorescence, and domain mapping. Ubiquitination assays evaluated USP13-mediated HIF-1α deubiquitination using K-specific ubiquitin mutants. Functional impacts were tested in CRC cell lines using CRISPR/Cas9-mediated USP13 knockout and overexpression. In vitro assays included proliferation (CCK-8), colony formation, migration, invasion, and angiogenesis (HUVECs tube formation). In vivo relevance was validated in xenograft models, USP13-knockout mice, and an AOM/DSS-induced CRC model. Clinical correlation used IHC staining of CRC patient tissues and TCGA data analysis. USP13 directly bound HIF-1α via its C-terminal UBA domain, cleaving K48-linked polyubiquitin chains to stabilize HIF-1α and enhance its transcriptional activity. USP13 knockout reduced HIF-1α levels, suppressed CRC cell proliferation, migration, invasion, and angiogenesis in vitro, and attenuated tumor growth in xenografts. Conversely, USP13 overexpression exacerbated these effects. Clinically, USP13 and HIF-1α levels correlated positively in CRC tissues and with Ki-67 expression. USP13 deficiency in mice reduced tumor burden in AOM/DSS models, decreased vascular density (CD31+), and downregulated VEGFA/Ki-67. Rescue experiments confirmed HIF-1α dependency for USP13-mediated oncogenic effects. USP13 promotes CRC progression by deubiquitinating and stabilizing HIF-1α, driving tumor growth, metastasis, and angiogenesis. This identifies USP13 as a pro-tumorigenic factor and potential therapeutic target in CRC.

13 May 2026 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
LGLijuan Gao
Lijuan Gao
SKShaobo Ke
Shaobo Ke
Background: Perioperative immunotherapy has significantly improved outcomes for patients with resectable esophageal squamous cell carcinoma (ESCC). Nevertheless, a substantial proportion of patients develop resistance to immunotherapy. This study aimed to identify biomarkers predictive of perioperative immunotherapy efficacy and elucidate the mechanisms underlying treatment resistance in non‐responders with resectable ESCC. Methods: RELB expression in ESCC clinical samples and prognosis was first assessed using tissue microarrays. Bisulfite sequencing and methylation‐specific PCR were employed to explore the mechanisms underlying RELB overexpression in ESCC. Subsequently, functional assays and western blot analysis were performed to evaluate the biological role of RELB in ESCC cells. Fifty‐nine tissue samples were collected from patients who received perioperative immunotherapy for ESCC at our center and categorized into progressive disease (PD) and stable disease (SD) groups. Triple‐label immunofluorescence staining, single‐cell RNA sequencing, and bulk‐RNA sequencing analyses were conducted to investigate the role of RELB in perioperative immunotherapy resistance. Results: A correlation was revealed between perioperative immunotherapy resistance in ESCC and RELB expression. RELB overexpression in ESCC tissues, which is regulated by DNA hypomethylation, exhibited a significant positive correlation with poor prognosis and advanced tumor stage. RELB knockdown inhibited the migration and proliferation of Eca109 and KYSE450 cells while promoting their apoptosis. The elevated RELB expression in patients with ESCC increased perioperative immunotherapy resistance by driving the mature dendritic cells enriched in immunoregulatory molecules (mregDCs)‐regulatory T cells (Tregs) axis for Treg recruitment and activation in the tumor microenvironment. Importantly, RELB was mainly enriched in and strongly correlated with the infiltration of mregDCs and Tregs. RELB+ mregDCs exhibited stronger interaction with Tregs and upregulation of IDO1 as well as activation of tryptophan metabolism. Conclusions: DNA hypomethylation‐induced RELB overexpression promoted perioperative immunotherapy resistance in ESCC by driving the mregDC‐Treg axis and is a potential predictive biomarker for perioperative immunotherapy response.